CoChat
Sign Up
Cited by 18Dementia and Cognitive Impairment ResearchNeurological Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

Is the distinction between Alzheimer's disease and vascular dementia possible and relevant?

Open access
Ravona-Springer, Ramit, Davidson, Michael, Noy, Shlomo·2003·Dialogues in Clinical Neuroscience
DOI 10.31887/dcns.2003.5.1/rravonaspringerPMC PMC3181710
Open this paper in CoChat — free account

Abstract

Advances in epidemiological, clinical, imaging, and neuropathological studies have undermined the clear distinction between vascular and Alzheimer-type dementia, which has characterized the last two decades of research in dementia. A significant degree of overlap between the two entities was demonstrated in terms of clinical expression, risk factors, and postmortem brain autopsy. In this article, we propose mechanisms by which cardiovascular risk factors might affect the manifestation of Alzheimer's disease, suggest possible explanations for the overlap with vascular dementia, and discuss the implications this might have on future differential diagnosis and treatment strategies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.31887/dcns.2003.5.1/rravonaspringer

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 119

  1. [1]Tomlinson BE. Blessed G. Roth M. Observations on the brains of demented old people J Neurol Sci. 1970 11 205 242 5505685
  2. [2]Hachinski VC. Lassen NA. Marshall J. Multi-infarct dementia: a cause of mental deterioration in the elderly Lancet. 1974 2 207 209 4135618
  3. [3]Hachinski VC. Miff LD. Zilhka E. et al. Cerebral blood flow in dementia. Arch Neurol. 1975 32 632 637 1164215
  4. [4]Perry E. Tomlinson BE. Blessed G. Bergmann K. Gibson PH. Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia BMJ. 1978 2 1457 1459 719462 PMC1608703
  5. [5]Perry EK. Perry RH. Blessed G. Tomlinson BE. Changes in brain cholinesterases in senile dementia of Alzheimer type Neuropathol Appl Neurobiol. 1978 4 273 277 703927
  6. [6]Bartus RT. Emerich DF. Cholinergic markers in Alzheimer disease JAMA. 1999 282 2208 2209 10605966
  7. [7]Lin L. Georgievska B. Mattsson A. Isacson O. Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation Proc Natl Acad Sci U S A. 1999 96 12108 12113 10518584 PMC18420
  8. [8]Isacson O. Lin L. Cholinergic modulation of amyloid processing and dementia in animal models of Alzheimer's disease Ann N Y Acad Sci. 2000 920 309 314 11193169
  9. [9]McKahnn G. Drachman D. Folstein M. Katzman R. Price D. Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease Neurology. 1984 34 939 944 6610841
  10. [10]Fisher CM. Dementia in cerebrovascular disease. In: Toole JF, Siekert RG, Whisnant JP, eds Cerebral Vascular Disease: Sixth Conference. New York, NY: Grune-Stratton 1968 232 236
  11. [11]Deutsch JA. The cholinergic synapse and the site of memory Science. 1971 174 788 794 4330469
  12. [12]Collerton D. Cholinergic function and intellectual decline in Alzheimer's disease Neuroscience. 1986 19 1 28 3537837
  13. [13]Perry EK. Gibson PH. Blessed G. Perry RH. Tomlinson BE. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue J Neurol Sci. 1977 34 247 265 144789
  14. [14]Babikian V. Ropper AH. Binswanger's disease: a review Stroke. 1987 18 2 12 3544352
  15. [15]Erkinjuntti T. Types of multi-infarct dementia Acta Neurol Scand. 1987 75 391 399 3630635
  16. [16]Roman GC. Senile dementia of the Binswanger type: a vascular form of dementia in the elderly JAMA. 1987 258 1782 1788 3625988
  17. [17]Chui HC. Victoroff Jl. Margolin D. Jagust W. Shankle R. Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the state of California Alzheimer's Disease Diagnostic and Treatment Centers Neurology. 1992 42 473 480 1549205
  18. [18]Roman GC. Tatemichi TK. Erkinjuntti T. et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop Neurology. 1993 43 250 260 8094895
  19. [19]Skoog I. The relationship between blood pressure and dementia: a review Biomed Pharmacother. 1997 51 367 375 9452785
  20. [20]Mirra SS. Heyman A. McKeel D. et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), Part II. Standardization of the neuropathologic assessment of Alzheimer's disease Neurology. 1991 41 479 486 2011243
  21. [21]Pantoni L. Pathophysiology of age-related cerebral white matter changes Cerebrovasc Dis. 2002 13(suppl 2) 7 10 11901236
  22. [22]Englund E. Neuropathology of white matter lesions in vascular cognitive impairment Cerebrovasc Dis. 2002 13(suppl 2) 11 15 11901237
  23. [23]Schmidt R. Schmidt H. Kapeller P. Lechner A. Fazekas F. Evolution of white matter lesions Cerebrovasc Dis. 2002 13(suppl 2) 16 20 11901238
  24. [24]Meyer JS. Xu G. Thornby J. Chowdhury MH. Quach M. Is mild cognitive impairment prodromal for vascular dementia like Alzheimer's disease? Stroke. 2002 33 1981 1985 12154249
  25. [25]Snowdon DA. Greiner LH. Mortimer JA. Riley KP. Greiner PA. Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study JAMA. 1997 277 813 817 9052711
  26. [26]Henon H. Durieu I. Guerouaou D. Lebert F. Pasquier F. Leys D. Poststroke dementia: incidence and relationship to prestroke cognitive decline Neurology. 2001 57 1216 1222 11591838
  27. [27]Kalaria RN. Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia Alzheimer Dis Assoc Disord. 1999 13(suppl 3) S115 S123 10609690
  28. [28]Kalaria RN. The role of cerebral ischemia in Alzheimer's disease Neurobiol Aging. 2000 21 321 330 10867217
  29. [29]Ott A. Stolk RP. Hofman A. van Harskamp F. Grobbee DE. Breteler MM. Association of diabetes mellitus and dementia: the Rotterdam Study Diabetologia. 1996 39 1392 1397 8933010
  30. [30]Breteler MM. Vascular risk factors for Alzheimer's disease: an epidemiological study Neurobiol Aging. 2000 21 153 160 10867200
  31. [31]Bots ML. van Kooten F. Haverkate F. et al. Coagulation and fibrinolysis markers and risk of dementia: the Dutch vascular factors in dementia study Haemostasis. 1998 28 216 222 10420069
  32. [32]Kalmijn S. Launer LJ. Lindemans J. Bots JL. Hofman A. Breteler MM. Total homocysteine and cognitive decline in a community-based sample of elderly subjects: the Rotterdam Study Am J Epidemiol. 1999 150 283 289 10430233
  33. [34]Graves AB. van Duijn CM. Chandra V. et al. for the EURODEM Risk Factors Research Group. Alcohol and tobacco consumption as risk factors for Alzheimer's disease: a collaborative re-analysis of case-controlled studies Int Epidemiol. 1991 20 S48 S57 1833354
  34. [35]Ott A. Breteler MM. van Harskamp F. et al. Prevalence of Alzheimer's disease and vascular dementia association with education: the Rotterdam Study BMJ. 1995 310 970 973 7728032 PMC2549358
  35. [36]Hofman A. Ott A. Breteler MMB. et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study Lancet. 1997 349 151 154 9111537
  36. [37]Breteler MM. Bots ML. Ott A. Hofman A. Risk factors for vascular disease and dementia Haemostasis. 1998 28 167 173 10420064
  37. [38]Kivipelto M. Helkala EL. Hanninen T. et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population-based study BMJ. 2001 322 1447 1451 11408299 PMC32306
  38. [39]Tyas SL. Manfreda J. Strain LA. Montgomery PR. Risk factors for Alzheimer's disease: a population-based, longitudinal study in Manitoba, Canada Int J Epidemiol. 2001 30 590 597 11416089
  39. [41]Notkola IL. Sulkava R. Pekkanen J. Erkinjuntti T. Ehnholm C. Kivinen P. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease Neuroepidemiology. 1998 17 14 20 9549720
  40. [42]Diaz-Arrastia R. Hyperhomocysteinemia: a new risk factor for Alzheimer's disease? Arch Neurol. 1998 55 1 2 9823822
  41. [44]Skyler JS. Oddo C. Diabetes trends in the USA Diabetes Metab Res Rev. 2002 18(suppl 3) S21 S26 12324981
  42. [45]Meigs JB. Epidemiology of the metabolic syndrome. 2002 Am J Manag Care. 2002 8(suppl) S283-S293 S292 -S296 12240700
  43. [46]Holmes C. Cairns N. Lantos P. et al. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies Br J Psychiatry. 1999 174 45 50 10211150
  44. [47]Neuropathology Group of the Medical Research Council Cognitive Function and Aged Study (MRC CFAS). Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales, Lancet. 2001 357 169 175 11213093
  45. [49]Moroney JT. Bagiella E. Desmond DW. et al. Meta-analysis of the Hachinski Ischemic Score in pathologically verified dementias Neurology. 1997 49 1096 1105 9339696
  46. [50]Swan GE. LaRue A. Carmelli D. Reed TE. Fabsitz RR. Decline in cognitive performance in aging twins. Heritability and biobehavioral predictors from the National Heart, Lung, and Blood Institute Twin Study Arch Neurol. 1992 49 476 481 1580808
  47. [51]Launer LJ. White LR. Petrovitch H. Ross GW. Curb JD. Cholesterol and neuropathologic markers of AD: a population-based autopsy study Neurology. 2001 57 1447 1452 11673587
  48. [52]Bonarek M. Barberger GP. Letenneur L. Deschamps V. Dubroka B. Datrigues JF. Relationships between cholesterol, apolipoprotein E polymorphism and dementia: a cross-sectional analysis from the PAQUID study Neuroepidemiology. 2000 19 141 148 10705232
  49. [53]Kabara JJ. A critical review of brain cholesterol metabolism Prog Brain Res. 1973 40 363 382 4608424
  50. [54]Morell P. Jurevics H. Origin of cholesterol in myelin Neurochem Res. 1996 21 463 470 8734440
  51. [55]Dietschy JM. Turley SD. Cholesterol metabolism in the brain Curr Opin Lipidol. 2001 12 105 112 11264981
  52. [56]Roheim PS. Carey M. Forte T. Vega GL. Apolipoproteins in human cerebrospinal fluid Proc Natl Acad Sci USA. 1979 76 4646 4649 291993 PMC411636
  53. [57]Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology Science. 1988 240 622 631 3283935
  54. [58]Simons M. Keller P. Dichgans J. Schulz JB. Cholesterol and Alzheimer's disease. Is there a link? Neurology. 2001 57 1089 1093 11571339
  55. [59]Simons M. Keller P. De Strooper B. Beyreuther K. Dotti CG. Simons K. Cholesterol depletion inhibits the generation of amyloid in hippocampal neurons Proc Natl Acad Sci U S A. 1998 95 6460 6464 9600988 PMC27798
  56. [60]Frears E. Stephens D. Walters C. Davies H. Austen B. The role of cholesterol in the biosynthesis of beta-amyloid Neuroreport. 1999 10 1699 1705 10501560
  57. [61]Kojro E. Gimpl G. Lammich S. Marz W. Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effects on the alpha-secretase ADAM 10 Proc Natl Acad Sci U S A. 2001 98 5815 5820 11309494 PMC33296
  58. [62]Wolozin B. Kellman W. Rousseau P. Celesia CC. Siegel G. Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors Arch Neurol. 2000 57 1439 1443 11030795
  59. [63]Jick H. Zornberg GL. Jick SS. Seshadri S. Drachman DA. Statins and the risk of dementia, Lancet. 2000 356 1627 1631 11089820
  60. [64]Crisby M. Carlson LA. Winblan B. Statins in the prevention and treatment of Alzheimer disease Alzheimer Dis Assoc Disord. 2002 16 131 136 12218642
  61. [65]Cucchiara B. Kasner SE. Use of statins in CNS disorders J Neurol Sci. 2001 187 81 89 11440749
  62. [66]Mahley RW. Rail SCJr. Apolipoprotein E: far more than a lipid transport protein Annu Rev Genomics Hum Genet. 2000 1 507 537 11701639
  63. [67]Eichner JE. Dunn ST. Perveen G. Thompson DM. Stewart KE. Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review Am J Epidemiol. 2002 155 487 495 11882522
  64. [68]Chapman J. Korczyn A. Karussis DM. Michaelson DM. The effects of APOE genotype on age at onset and progression of neurodegenerative diseases Neurology. 2001 57 1482 1485 11673593
  65. [69]Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease Trends Neurosci. 1994 17 525 530 7532337
  66. [70]Prince M. Lovestone S. Cervilla J. et al. The association between APOE and dementia does not seem to be mediated by vascular factors Neurology. 2000 54 397 402 10668701
  67. [71]Haraki T. Takegoshi T. Kitoh C. et al. Carotid artery intima-media thickness and brachial artery flow-mediated vasodilation in asymptomatic Japanese male subjects amongst apolipoprotein E phenotypes J Intern Med. 2002 252 114 120 12190886
  68. [72]Djousse L. Myers RH. Province MA. et al. Influence of apolipoprotein E, smoking, and alcohol intake on carotid atherosclerosis: National Heart, Lung, and Blood Institute Family Heart Study Stroke. 2002 33 1357 1361 11988615
  69. [73]Humphries SE. Talmud PJ. Hawe E. Bolla M. Day IN. Miller GJ. Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study Lancet. 2001 358 115 119 11463413
  70. [74]Lambert JC. Brousseau T. Defosse V. et al. Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentrations: the ECTIM study Hum Mol Genet. 2000 9 57 61 10587578
  71. [75]Lahoz C. Schaefer EJ. Cupples LA. et al. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study Atherosclerosis. 2001 154 529 537 11257253
  72. [76]Scuteri A. Bos AJ. Zonderman AB. Brant LJ. Lakatta EG. Fleg JL. Is the apoE4 allele an independent predictor of coronary events? Am J Med. 2001 110 28 32 11152862
  73. [77]Slooter AJ. Tang MX. van Duijn CM. et al. Apolipoprotein E epsilon4 and the risk of dementia with stroke. A population-based investigation JAMA. 1997 277 818 821 9052712
  74. [78]Premkumar DR. Cohen DL. Hedera P. Friedland RP. Kalaria RN. Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease Am J Pathol. 1996 148 2083 2095 8669492 PMC1861657
  75. [79]Jarrett RJ. Epidemiology and public health aspects of non-insulindependent diabetes mellitus Epidemiol Rev. 1989 11 151 171 2680553
  76. [80]Stegmayr B. Asplund K. Diabetes as a risk factor for stroke. A population perspective Diabetologia. 1995 38 1061 1068 8591820
  77. [81]Skoog I. Risk factors for vascular dementia: a review Dementia. 1994 5 137 144 8087168
  78. [82]Tatemichi TK. Desmond DW. Paik M. et al. Clinical determinants of dementia related to stroke Ann Neurol. 1993 33 568 575 8498836
  79. [83]Luchsinger JA. Tang MX. Stern Y. Shea S. Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort Ami J Epidemiol. 2001 154 635 641 11581097
  80. [85]Landin K. Blennow K. Wallin A. Gottfries CG. Low blood pressure and blood glucose levels in Alzheimer's disease. Evidence for a hypometabolic disorder? J Intern Med. 1993 233 357 363 8463769
  81. [86]Nielson KA. Nolan JH. Berchtold NC. Sandman CA. Mulnard RA. Cotman CW. Apolipoprotein-E genotype of diabetic dementia patients: is diabetes rare in Alzheimer's disease? J Am Geriatr Soc. 1996 44 897 904 8708297
  82. [87]Vanhanen M. Kuusisto J. Koivisto K. et al. Type 2 diabetes and cognitive function in a non-demented population Acta Neurol Scand. 1999 100 97 101 10442450
  83. [88]Curb JD. Rodriguez BL. Abbott RD. et al. Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance Neurology. 1999 52 971 975 10102414
  84. [89]Munch G. Mayer S. Michaelis J. et al. Influence of advanced glycation endproducts and AGE inhibitors on nucleation-dependent polymerization of beta-amyloid peptide Biochim BiophysActa. 1997 1360 17 29 9061036
  85. [90]Dickson DW. Sinicropi S. Yen SH. et al. Glycation and microglial reaction in lesions of Alzheimer's disease Neurobiol Aging. 1996 17 733 733 8892346
  86. [91]Mukherjee A. Song E. Kihiko-Ehmann M. et al. Insulin hydrolyzes amyloid peptides to products that are neither neurotoxic nor deposit on amyloid plaques J Neurosci. 2000 20 8745 8749 11102481 PMC6773064
  87. [92]Qiao Qiu W. Walsh DM. Ye Z. et al. Insulin-degrading enzyme regulates extracellular levels of amyloid p-protein by degradation J Biol Chem. 1998 273 32730 32738 9830016
  88. [93]Stolk RP. Breteler MM. Ott A. et al. Insulin and cognitive function in an elderly population. The Rotterdam Study Diabetes Care. 1997 20 792 795 9135944
  89. [97]Unger J. McNeill TH. Moxley RT. White M. Moss A. Livingston JN. Distribution of insulin receptor-like immunoreactivity in the rat forebrain Neuroscience. 1989 31 143 157 2771055
  90. [98]Petrovich H. White LR. Izmirilian G. et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS, Honolulu-Asia Aging Study Neurobiol Aging. 2000 21 57 62 10794849
  91. [99]Nag S. Cerebral changes in chronic hypertension: combined permeability and immunohistochemical studies Acta Neuropathol (Bert). 1984 62 178 184 6695553
  92. [100]Johansson BB. Pathogenesis of vascular dementia: the possible role of hypertension Dementia. 1994 5 174 176 8087174
  93. [101]Wallin A. Sjogren M. Edman A. Blennow K. Regland B. Symptoms, vascular risk factors and blood-brain barrier function in relation to CT whitematter changes in dementia Eur Neurol. 2000 44 229 235 11096223
  94. [102]Wallin A. The overlap between Alzheimer's disease and vascular dementia: the role of white matter changes Dement Geriatr Cogn Disord. 1998 9(suppl 1) 30 35 9716242
  95. [103]Launer LJ. Masaki K. Petrovich H. Foley D. Havlik RJ. The association between midlife blood pressure levels and late life cognitive function. The Honolulu-Asia Aging Study JAMA. 1995 274 1846 1851 7500533
  96. [104]Peila R. White LR. Petrovich H. et al. Joint effect of the APOE gene and midlife systolic blood pressure on late life cognitive impairment. The Honolulu Asia Aging Study Stroke. 2001 32 2882 2889 11739991
  97. [105]Carmelli D. Swan GE. Reed T. et al. Midlife cardiovascular risk factors, ApoE, and cognitive decline in elderly male twins Neurology. 1998 50 1580 1585 9633697
  98. [106]Elias MF. Wolf PA. D'Agostino RB. Cobb J. White LR. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham study Am J Epidemiol. 1993 138 353 364 8213741
  99. [107]Skoog I. 15-year longitudinal study of blood pressure and dementia Lancet. 1996 347 1141 1145 8609748
  100. [108]Swan GE. LaRue A. Carmelli D. Reed TE. Fabsitz RR. Decline in cognitive performance in aging twins. Heritability and biobehavioral predictors from the National Heart, Lung, and Blood Institute Twin Study Arch Neurol. 1992 49 476 481 1580808
  101. [110]Kilander L. Nyman H. Boberg M. Hansson L. Lithell H. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men Hypertension. 1998 31 780 786 9495261
  102. [111]Kalmijn S. Feskens EJ. Launer LJ. Kromhout D. Cerebrovascular disease, the ApoE4 allele and cognitive decline in a community-based study of elderly men Stroke. 1996 27 2230 2235 8969786
  103. [112]Swain RA. St Clair L. The role of folic acid in deficiency states and prevention of disease J Earn Pract. 1997 44 138 144 9040515
  104. [113]Elkind MS. Sacco RL. Stroke risk factors and stroke prevention Semin Neurol. 1998 18 429 440 9932614
  105. [114]Duthie SJ. Folic acid deficiency and cancer: mechanisms of DNA instability Br Med Bull. 1999 55 578 592 10746348
  106. [115]Leblhuber F. Walli J. Artner-Dworzak E. et al. Hyperhomocysteinemia in dementia J Neural Transm. 2000 107 1469 1474 11458999
  107. [116]Seshadri S. Beiser A. Selhub J. et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease N Engl J Med. 2002 346 476 483 11844848
  108. [117]Vermeer SE. van Dijk EJ. Koudstaal PJ. et al. Homocysteine, silent brain infarcts, and white matter lesions: The Rotterdam Scan Study Ann Neurol. 2002 51 285 289 11891822
  109. [118]De Groot JC. De Leeuw FE. Qudkerk M. et al. Periventricular cerebral white matter lesions predict rate of cognitive decline Ann Neurol. 2002 52 335 341 12205646
  110. [119]Lipton SA. Kim WK. Choi YB. et al. Neurotoxicity associated with dual actions of homocysteine at the A/-methyl-D-aspartate receptor Proc Natl Acad Sci U SA. 1997 94 5923 5928 PMC20882 9159176
  111. [120]Kruman II. Culmsee C. Chan SL. et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity J Neurosci. 2000 20 6920 6926 10995836 PMC6772815
  112. [121]Kruman II. Kumaravel TS. Lohani A. et al. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease J Neurosci. 2002 22 1752 1762 11880504 PMC6758871
  113. [122]Cheng A. Braunstein JB. Dennison C. Nass C. Blumenthal RS. Reducing global risk for cardiovascular disease: using lifestyle changes and pharmacotherapy Clin Cardiol. 2002 25 205 212 12018878 PMC6653857
  114. [123]Stampfer MJ. Hu FB. Manson JE. Rimm EB. Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle N Engl J Med. 2000 343 16 22 10882764
  115. [124]Platz EA. Willet WC. Colditz GA. Rimm EB. Spiegelman D. Giovannucci E. Proportion of colon cancer risk that might be preventable in a cohort of middle-aged US men Cancer Causes Control. 2000 11 579 588 10977102
  116. [125]Lindsay J. Laurin D. Verreault R. et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging Am J Epidemiol. 2002 156 445 453 12196314
  117. [126]Laurin D. Verreault R. Lindsay J. MacPherson K. Rockwood K. Physical activity and risk of cognitive impairment and dementia in elderly persons Arch Neurol. 2001 58 498 504 11255456
  118. [127]Friedland RP. Fritsch T. Smyth KA. et al. Patients with Alzheimer's disease have reduced activities in midlife compared with healthy controlgroup members Proc Natl Acad Sci U S A. 2001 98 3440 3445 11248097 PMC30672
  119. [128]Ruitenberg A. van Swieten JC. Witteman JC. et al. Alcohol consumption and risk of dementia: the Rotterdam Study Lancet. 2002 359 281 286 11830193

Cited by

Sorted by citations

Authors
Ravona-Springer, R., Davidson, M., & Noy, S.
Affiliations
  • Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
  • Tel Aviv University (IL)
Corresponding author
Davidson, Michael
ORCID
Davidson, Michael
Venue
Dialogues in Clinical Neuroscience
Publisher
Informa UK Limited
Published
2003-03-31
Volume
5
Issue
1
Pages
7-15
ISSN
  • 1294-8322 (ISSN-L)
  • 1958-5969
DOI
10.31887/dcns.2003.5.1/rravonaspringer
PMC
PMC3181710
OpenAlex
W4320803765
Cited by
18
References
10
Citations by year
2025: 1 · 2024: 3 · 2023: 3 · 2021: 3 · 2020: 3 · 2019: 1 · 2016: 1 · 2014: 2
FWCI
0.00
Type
journal article
Language
en
Open access
Licence
Locations
  • Dialogues in Clinical Neuroscience (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
Alzheimer's disease, vascular dementia, dementia subtypes, differential diagnosis, cardiovascular risk factors, postmortem neuropathology, clinical overlap, neuropathology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review